PDS Biotechnology (PDSB) Latest Cancer Clinical Results
b'PDS Biotechnology (PDSB) stock price is up over 61% this past year. PDS Biotechnology director, president, and CEO, Dr. Frank Bedu, weighs in on the latest trial results that indicated 100% clinical response for treatment of cervical cancer patients with large tumors using a combination of PDS101 with standard-of-care chemoradiotherapy. All patients had a tumor shrinkage of 60% or greater.'